XTX Topco’s Adaptimmune Therapeutics ADAP Stock Holding History

XTX Topco’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-353,836	Closed	-$9.2K	–	3781
2025 Q4	$9.2K	Buy	353,836 +251,335	+245%	+$34.1K	﹤0.01%	3190
2025 Q3	$13.3K	Buy	102,501 +22,479	+28%	+$3.08K	﹤0.01%	2401
2025 Q2	$19.2K	Buy	+80,022	New	+$21.4K	﹤0.01%	2170
2024 Q3	–	Sell	-12,399	Closed	-$12.1K	–	2028
2024 Q2	$12.1K	Sell	12,399 -3,553	-22%	-$3.9K	﹤0.01%	1673
2024 Q1	$25.2K	Sell	15,952 -21,025	-57%	-$25.4K	﹤0.01%	1584
2023 Q4	$29.3K	Buy	+36,977	New	+$20.8K	0.01%	1312
2022 Q1	–	Sell	-17,560	Closed	-$66K	–	639
2021 Q4	$66K	Buy	+17,560	New	+$79.9K	0.04%	531

Other funds holding ADAP

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

XTX Topco's ADAP Position: Q1 2026 in Review

XTX Topco sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 353,836 shares — an estimated $9.2K sold.

XTX Topco first reported a position in ADAP in Q4 2021 and held it in 7 quarters. The position peaked at $66K in Q4 2021. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.

XTX Topco reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
XTX Topco sold 353,836 Adaptimmune Therapeutics shares in Q1 2026, an estimated $9.2K.
XTX Topco first reported a position in Adaptimmune Therapeutics in Q4 2021 and held it in 7 quarters.
XTX Topco's Adaptimmune Therapeutics position peaked at $66K in Q4 2021.
1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.